The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.

A patient found to carry a BRCA1 pathogenic variant is not referred to a certified genetic counselor in her health system.

With permission from a data safety monitoring committee, the firm will begin treating a second cohort with AMT-162 in the EPISOD1 trial in early 2025.

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.